Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Dive

Showing results (191-200 of 207) with videos related to

Pageof 21
Sort By:
Oncogene|September 1, 2009
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell deathD A Tennant, C Frezza, E D MacKenzie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2019
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trialR Y Tay, F Fernández-Gutiérrez, V Foy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2011
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1S J Danson, P Johnson, T H Ward, et al.
British Journal of Cancer|October 29, 2009
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II studyR E Board, G Ellison, M C M Orr, et al.
Cancer Biomarkers : Section a of Disease Markers|May 2, 2009
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarkerM Hägg Olofsson, J Cummings, W Fayad, et al.
British Journal of Cancer|September 17, 2009
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cellsD L Roberts, K J Williams, R L Cowen, et al.
Cell Death & Disease|May 4, 2013
A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkersK L Simpson, C Cawthorne, C Zhou, et al.
Immuno-Oncology Technology|May 2, 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trialK S Shohdy, M Pillai, K S Abbas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNAG Gremel, R J Lee, M R Girotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2010
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapyC L Mitchell, J P B O'Connor, A Jackson, et al.
Pageof 21

Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Oncogene|September 1, 2009
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell deathD A Tennant, C Frezza, E D MacKenzie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2019
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trialR Y Tay, F Fernández-Gutiérrez, V Foy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2011
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1S J Danson, P Johnson, T H Ward, et al.
British Journal of Cancer|October 29, 2009
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II studyR E Board, G Ellison, M C M Orr, et al.
Cancer Biomarkers : Section a of Disease Markers|May 2, 2009
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarkerM Hägg Olofsson, J Cummings, W Fayad, et al.
British Journal of Cancer|September 17, 2009
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cellsD L Roberts, K J Williams, R L Cowen, et al.
Cell Death & Disease|May 4, 2013
A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkersK L Simpson, C Cawthorne, C Zhou, et al.
Immuno-Oncology Technology|May 2, 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trialK S Shohdy, M Pillai, K S Abbas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNAG Gremel, R J Lee, M R Girotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2010
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapyC L Mitchell, J P B O'Connor, A Jackson, et al.
Pageof 21